Abstract
The role of complement in the development and regulation of antibody responses under both healthy and pathological conditions is known for long. Unraveling the elements involved and the molecular mechanisms underlying the events however is still in progress. This review focuses on the role of complement receptors CR1 (CD35) and CR2 (CD21) expressed on B lymphocytes, which interact with ligands generated upon activation of component C3, the major protein of the complement cascade. The binding and possible effects of immune complexes comprising antigen, antibody and complement on B-cell activation are discussed. Results of clinical studies of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis and conclusions drawn from animal models used to investigate various aspects of human diseases are also debated. We discuss similarities regarding the overall structure and certain functions of complement and complement receptors in mice and men however, call the attention to major differences regarding tissue distribution and their role in B-cell functions.
Keywords: complement, b cell, regulation, autoimmunity
Current Pharmaceutical Design
Title: Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Volume: 9 Issue: 23
Author(s): Anna Erdei, Jozsef Prechl, Andrea Isaak and Eszter Molnar
Affiliation:
Keywords: complement, b cell, regulation, autoimmunity
Abstract: The role of complement in the development and regulation of antibody responses under both healthy and pathological conditions is known for long. Unraveling the elements involved and the molecular mechanisms underlying the events however is still in progress. This review focuses on the role of complement receptors CR1 (CD35) and CR2 (CD21) expressed on B lymphocytes, which interact with ligands generated upon activation of component C3, the major protein of the complement cascade. The binding and possible effects of immune complexes comprising antigen, antibody and complement on B-cell activation are discussed. Results of clinical studies of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis and conclusions drawn from animal models used to investigate various aspects of human diseases are also debated. We discuss similarities regarding the overall structure and certain functions of complement and complement receptors in mice and men however, call the attention to major differences regarding tissue distribution and their role in B-cell functions.
Export Options
About this article
Cite this article as:
Erdei Anna, Prechl Jozsef, Isaak Andrea and Molnar Eszter, Regulation of B-Cell Activation by Complement Receptors CD21 and CD35, Current Pharmaceutical Design 2003; 9 (23) . https://dx.doi.org/10.2174/1381612033454351
DOI https://dx.doi.org/10.2174/1381612033454351 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy TNF-α in Tuberculosis: A Cytokine with a Split Personality
Inflammation & Allergy - Drug Targets (Discontinued) Liquid Chromatographic Analysis of Methotrexate and Minocycline-relevance to the Determination in Plasma/Nanoparticulate Formulations
Current Chromatography Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology Statins And Stroke
Current Medicinal Chemistry Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals
Current Drug Safety miRNA-146a Improves Immunomodulatory Effects of MSC-derived Exosomes in Rheumatoid Arthritis
Current Gene Therapy Sole Anti-inflammatory Immunomodulators: Innovative Drugs to Prevent and Treat Autoimmune Diseases and Proteopathies
Current Chinese Science The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets The Glucocorticoid Receptor: Molecular Mechanism and New Therapeutic Opportunities
Current Drug Targets - Inflammation & Allergy Laboratory Biomarkers for Guiding Therapy with Methotrexate in Rheumatoid Arthritis
Current Pharmaceutical Design Neopterin as a Marker for Immune System Activation
Current Drug Metabolism